Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
KPTI Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
11.50%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
85.90%
KPTI Stock Analysis
KPTI
PE Ratio:
KPTI
PEG Ratio:
Not Available
KPTI
Forward EPS Growth (12 month):
0.00%
KPTI
PS Ratio:
1.3
KPTI
PSG Ratio:
0.1
KPTI
Forward Revenue Growth (12 month):
16.70%
KPTI Articles
No data was found